Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson's disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson's with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/08/18 | $75,000,000 | Series A |
Adage Capital Management Alexandria Venture Investments Boxer Capital BVF Partners EcoR1 Capital Omega Funds OrbiMed Advisors Pontifax RA Capital | undisclosed |
